Free Trial
NASDAQ:KRBP

Kiromic BioPharma 8/9/2024 Earnings Report

Kiromic BioPharma EPS Results

Actual EPS
-$0.74
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Kiromic BioPharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Kiromic BioPharma Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Kiromic BioPharma's next earnings date is estimated for Thursday, May 8, 2025, based on past reporting schedules.

Conference Call Resources

Kiromic BioPharma Earnings Headlines

From Social Security to Social Prosperity?
In less than a decade, Social Security could be out of money. But a surprising plan from Trump’s inner circle may not just save the system — it could unlock a major opportunity for savvy investors. Financial insider Jim Rickards calls it “Social Prosperity,” and says those who act now could see the biggest gains.
Kiromic BioPharma Files for Chapter 7 Bankruptcy
Kiromic says Deltacel-01 trial patient reaches progression-free survival
See More Kiromic BioPharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiromic BioPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiromic BioPharma and other key companies, straight to your email.

About Kiromic BioPharma

Kiromic BioPharma (NASDAQ:KRBP), a clinical stage biotherapeutics company, utilizes engineered and non-engineered Gamma Delta T cell (GDT) technologies to develop therapies for solid tumors. The company develops Deltacel-01, which is in Phase 1 clinical trial, for patients with non-small cell lung cancer; Isocel in combination with low-dose radiation to treat Mesothelin Isoform 2 positive solid malignancies; ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; Procel in combination with low-dose radiation to treat PD-L1 positive solid malignancies; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has a license agreement with Longwood University; and a research and development collaboration agreement with Molipharma, S.R.L. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.

View Kiromic BioPharma Profile

More Earnings Resources from MarketBeat